克拉斯
生物
融合基因
ROS1型
计算生物学
可药性
基因
癌症
鉴定(生物学)
癌症研究
生物信息学
遗传学
突变
腺癌
植物
作者
Sebastian Uhrig,Julia Ellermann,Tatjana Walther,Pauline Burkhardt,Martina Fröhlich,Barbara Hutter,Umut H. Toprak,Olaf Neumann,Albrecht Stenzinger,Claudia Scholl,Stefan Fröhling,Benedikt Brors
出处
期刊:Genome Research
[Cold Spring Harbor Laboratory Press]
日期:2021-01-13
卷期号:31 (3): 448-460
被引量:320
标识
DOI:10.1101/gr.257246.119
摘要
The identification of gene fusions from RNA sequencing data is a routine task in cancer research and precision oncology. However, despite the availability of many computational tools, fusion detection remains challenging. Existing methods suffer from poor prediction accuracy and are computationally demanding. We developed Arriba, a novel fusion detection algorithm with high sensitivity and short runtime. When applied to a large collection of published pancreatic cancer samples ( n = 803), Arriba identified a variety of driver fusions, many of which affected druggable proteins, including ALK, BRAF, FGFR2, NRG1, NTRK1, NTRK3, RET, and ROS1. The fusions were significantly associated with KRAS wild-type tumors and involved proteins stimulating the MAPK signaling pathway, suggesting that they substitute for activating mutations in KRAS . In addition, we confirmed the transforming potential of two novel fusions, RRBP1 - RAF1 and RASGRP1 - ATP1A1 , in cellular assays. These results show Arriba's utility in both basic cancer research and clinical translation.
科研通智能强力驱动
Strongly Powered by AbleSci AI